News

Filter

Current filters:

Escitalopram Oxalate

1 to 9 of 90 results

Actavis brings escitalopram to market after patent expiry

Actavis brings escitalopram to market after patent expiry

02-06-2014

Generics major Actavis (NYSE: ACT) has launched escitalopram tablets in the UK today, following the patent…

ActavisCNS DiseasesEscitalopramEscitalopram OxalateGenericsLexaproLundbeckPatentsUK

Lundbeck infringement action against escitalopram generics in Spain is dismissed

02-09-2011

In a judgment issued last month, Spain’s Barcelona Commercial Court Number 4 rejected the infringement…

CipralexDr Reddy's LaboratoriesEscitalopram OxalateEuropeGenericsLegalLundbeckNeurologicalPatentsPharmaceutical

Lundbeck partner Mochida files for escitalopram approval in Japan

17-09-2010

Danish drugmaker Lundbeck A/S (LUND: DC) says that its partner Mochida Pharmaceutical (4534: JP) has…

Asia-PacificCipralexEscitalopram OxalateLundbeckMarkets & MarketingMochida PharmaceuticalNeurologicalPharmaceuticalRegulation

Zacks analysts view AstraZeneca/Forest deal favorably

18-08-2009

Following the announcement on August 12 by UK drug major AstraZeneca that it has entered into a co-development…

Advair DiskusAstraZenecaEscitalopram OxalateEuropeFloventFlovent DiskusFluticasone PropionateForest LaboratoriesGlaxoSmithKlineGSKLexaproNorth AmericaNycomedPharmaceutical

Lundbeck shares driven up by higher profit

15-05-2009

Danish drugmaker H Lundbeck's profit for the first quarter of 2009 was up 3% year-on-year, due to rising…

AzilectEscitalopram OxalateLexaproLundbeckRasagiline

1 to 9 of 90 results

COMPANY SPOTLIGHT

Menarini

Back to top